|Title:||Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia||Authors:||Lee C.-Y.
|Issue Date:||2007||Journal Volume:||97||Journal Issue:||7||Start page/Pages:||877-882||Source:||British Journal of Cancer||Abstract:||
Bone marrow (BM) neoangiogenesis plays an important role in acute myelogenous leukaemia (AML), and depends on the interplay of members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) families. We determined the marrow levels of seven molecules associated with angiogenesis in 52 AML patients before chemotherapy and 20 healthy controls: VEGF-A, VEGF/PlGF, VEGF-C, VEGF-D, Ang-1, Ang-2, and Tie-2. All the molecules were quantified using enzyme-linked immunosorbent assay (ELISA). Comparing to normal controls, the marrow levels of VEGF/PlGF, Ang-2, and Tie-2 were significantly higher, and those of VEGF-C and Ang-1 were significantly lower in the AML patients (P<0.001). A total of 31 patients were further subjected to survival analysis. Patients with lower Tie-2 (<26 ng ml-1) and Ang-2 levels (<4500 pg ml-1) displayed a survival advantage (P=0.037 and 0.042, respectively), same as patients with higher VEGF/PlGF (?1 pg ml -1) and VEGF-D levels (?350 pg ml-1) (P=0.020 and 0.016, respectively). An angio-index ((Ang-2 x Tie-2)/(VEGF/PlGF x VEGF-D)) was established and multivariate Cox regression analysis revealed that patients with higher angio-index values (?50) displayed poor prognosis (hazard ratio 5.91, 95% confidence interval 1.99-17.56; P=0.001). The angio-index is closely associated with the clinical outcome of AML patients and may be valuable in disease prognosis. ? 2007 Cancer Research.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/502711||ISSN:||0007-0920||DOI:||10.1038/sj.bjc.6603966||SDG/Keyword:||angiogenic factor; angiopoietin; biological marker; vasculotropin; vasculotropin A; vasculotropin C; acute granulocytic leukemia; adult; article; cancer survival; controlled study; enzyme linked immunosorbent assay; female; human; major clinical study; male; priority journal; prognosis; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Angiopoietin-1; Angiopoietin-2; Bone Marrow; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neovascularization, Pathologic; Prognosis; Receptor, TIE-2; Sensitivity and Specificity; Tumor Markers, Biological; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D
|Appears in Collections:||醫學檢驗暨生物技術學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.